Fact Check: Retatrutide lowered non-HDL cholesterol by up to 27% and Apo B by up to 24% in a study presented at ...

Claim: Retatrutide lowered non-HDL cholesterol by up to 27% and Apo B by up to 24% in a study presented at a heart conference in 2024.

Verdict: Partially True (80% confidence)

Explanation: According to Peptides Explorer, retatrutide lowered non-HDL cholesterol by 26.9% and Apo B by 24.2% in a study, which supports the claim's figures for Apo B but not for non-HDL cholesterol. The Lancet also confirms reductions in non-HDL cholesterol and Apo B, aligning with the claim's outcomes. Clinical Trials Arena reports that the study was presented at a heart conference in 2024, confirming the context and timeframe. Therefore, while the claim is partially supported, the exact figures for non...